Vanda Pharmaceuticals Inc Dossier - Source-backed chat

Vanda Pharmaceuticals Inc

VNDANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.76

Intrinsic Value $5.83median of 2 methodsbased on filings through 30 Jun 2026

Market Price $4.91Price as of 30 Sep 2026

UndervaluedIntrinsic value is 19% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $296.9M

Enterprise Value $241M

Shares Outstanding 60M diluted

Next Earnings Date12 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Vanda Pharmaceuticals is undergoing a significant commercial and clinical transformation. While its legacy sleep franchise HETLIOZ faces ongoing generic erosion, the company has successfully diversified its revenue streams. Growth is driven by strong double-digit momentum in Fanapt sales, the recent FDA approval of BYSANTI, and the innovative direct-to-consumer launch of NEREUS for motion-induced vomiting. With a robust cash position, raised full-year 2026 revenue guidance, and a highly anticipated PDUFA date for imsidolimab in December 2026, Vanda represents an attractive specialty biopharma turnaround play with substantial near-term catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.50

Mean target$14.13

High · most bullish analyst$21.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.5015%

Generic competition for HETLIOZ accelerates faster than expected, while the launches of NEREUS and BYSANTI face slow physician adoption and payer restrictions. The FDA issues a Complete Response Letter (CRL) or delays the approval of imsidolimab, and VQW-765 fails to meet its primary endpoints in social anxiety disorder. Elevated SG&A and R&D expenses lead to a higher-than-expected cash burn, eroding the company's cash reserves.

Base CaseCentral scenario

$14.1360%

Matches the consensus mean

Vanda successfully executes its commercial launches, meeting its raised full-year 2026 revenue guidance of $240M-$290M. Fanapt remains the primary growth engine, offsetting the decline in HETLIOZ. Imsidolimab receives FDA approval in December 2026, and VQW-765 clinical readouts support further development. The company's strong balance sheet ($202.3M in cash and marketable securities) provides sufficient runway to fund these launches and pipeline advancements.

Bull CaseUpside scenario

$21.0025%

NEREUS achieves rapid adoption through its pioneering direct-to-consumer platform, exceeding the high end of its $10M-$30M guidance. BYSANTI launches strongly in H2 2026, and the FDA approves imsidolimab for GPP on or before its December 12, 2026 PDUFA date, establishing a high-margin rare disease franchise. Fanapt continues its strong double-digit growth trajectory, and VQW-765 delivers positive Phase III results in social anxiety disorder by year-end.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial execution with Fanapt net product sales growing 26% year-over-year in Q1 2026.
Innovative direct-to-consumer commercial model launched for NEREUS (tradipitant) via nereus.us, bypassing traditional pharmacy friction.
Diversified near-term product portfolio with the FDA approval of BYSANTI (milsaperidone) and the integration of PONVORY.
Robust balance sheet with $202.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and no significant debt.
High-impact regulatory catalyst with a PDUFA target action date of December 12, 2026, for imsidolimab in generalized pustular psoriasis (GPP).

Key Investment Risks

Continued revenue erosion of HETLIOZ due to aggressive U.S. generic competition.
Widening net losses ($48.6 million in Q1 2026) driven by high launch-related SG&A expenses and ongoing R&D investments.
Regulatory risks associated with the upcoming FDA review of imsidolimab and clinical trial execution risks for late-stage pipeline assets.
Payer and reimbursement hurdles for newly launched branded therapies in competitive CNS and psychiatric markets.

Thesis Invalidation Triggers

A regulatory rejection or significant delay of imsidolimab by the FDA on or before the December 12, 2026 PDUFA date.
Failure of full-year 2026 revenues to meet the guided range of $240 million to $290 million.
A rapid acceleration of cash burn that threatens the company's 12-to-18 month operational runway.
Negative top-line Phase III data for VQW-765 in social anxiety disorder.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.